[ad_1]
Solar, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that prompts the sort I interferon pathway. Science 339, 786–791 (2013).
Wu, J. et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339, 826–830 (2013).
Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, kind I interferon-dependent innate immunity. Nature 461, 788–792 (2009).
Chen, Q., Solar, L. & Chen, Z. J. Regulation and performance of the cGAS–STING pathway of cytosolic DNA sensing. Nat. Immunol. 17, 1142–1149 (2016).
Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced kind I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843–852 (2014).
Pantelidou, C. et al. PARP inhibitor efficacy relies on CD8+ T-cell recruitment by way of intratumoral sting pathway activation in BRCA-deficient fashions of triple-negative breast most cancers. Most cancers Discov. 9, 722–737 (2019).
Wang, Z. et al. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J. Clin. Make investments. 129, 4850–4862 (2019).
Parkes, E. E. et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA injury in breast most cancers. J. Natl Most cancers Inst. 109, djw199 (2017).
Mender, I. et al. Telomere stress potentiates STING-dependent anti-tumor immunity. Most cancers Cell 38, 400–411.e6 (2020).
Lara, P. N. et al. Randomized section III placebo-controlled trial of carboplatin and paclitaxel with or with out the vascular disrupting agent vadimezan (ASA404) in superior non-small-cell lung most cancers. J. Clin. Oncol. 29, 2965–2971 (2011).
Gao, P. et al. Binding-pocket and lid-region substitutions render human STING delicate to the species-specific drug DMXAA. Cell Rep. 8, 1668–1676 (2014).
Ding, C., Track, Z., Shen, A., Chen, T. & Zhang, A. Small molecules concentrating on the innate immune cGAS‒STING‒TBK1 signaling pathway. Acta Pharm. Sin. B 10, 2272–2298 (2020).
Meric-Bernstam, F. et al. Section Ib research of MIW815 (ADU-S100) together with spartalizumab (PDR001) in sufferers (pts) with superior/metastatic strong tumors or lymphomas. J. Clin. Oncol. 37, 2507–2507 (2019).
Pan, B. S. et al. An orally accessible non-nucleotide STING agonist with antitumor exercise. Science https://doi.org/10.1126/science.aba6098 (2020).
Solar, X. et al. Amplifying STING activation by cyclic dinucleotide–manganese particles for native and systemic most cancers metalloimmunotherapy. Nat. Nanotechnol. 16, 1260–1270 (2021).
Yao, Y. et al. Nanoparticle-based drug supply in most cancers remedy and its function in overcoming drug resistance. Entrance. Mol. Biosci. 7, 193 (2020).
Irvine, D. J. & Dane, E. L. Enhancing most cancers immunotherapy with nanomedicine. Nat. Rev. Immunol. 20, 321–334 (2020).
Sykes, E. A., Chen, J., Zheng, G. & Chan, W. C. W. Investigating the influence of nanoparticle dimension on energetic and passive tumor concentrating on effectivity. ACS Nano 8, 5696–5706 (2014).
Duan, X. et al. Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. Nat. Commun. 10, 1899 (2019).
Corrales, L. et al. Direct activation of STING within the tumor microenvironment results in potent and systemic tumor regression and immunity. Cell Rep. 11, 1018–1030 (2015).
Lemos, H. et al. Overcoming resistance to STING agonist remedy to incite sturdy protecting antitumor immunity. J. Immunother. Most cancers 8, e001182 (2020).
Bulbake, U., Doppalapudi, S., Kommineni, N. & Khan, W. Liposomal formulations in medical use: an up to date overview. Pharmaceutics 9, 12 (2017).
Fang, J., Nakamura, H. & Maeda, H. The EPR impact: distinctive options of tumor blood vessels for drug supply, components concerned, and limitations and augmentation of the impact. Adv. Drug Deliv. Rev. 63, 136–151 (2011).
Kingston, B. R. et al. Particular endothelial cells govern nanoparticle entry into strong tumors. ACS Nano 15, 14080–14094 (2021).
Yang, H. et al. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade. J. Clin. Make investments. 129, 4350–4364 (2019).
Barber, G. N. STING: an infection, irritation and most cancers. Nat. Rev. Immunol. 15, 760–770 (2015).
Xia, T., Konno, H., Ahn, J. & Barber, G. N. Deregulation of STING signaling in colorectal carcinoma constrains DNA injury responses and correlates with tumorigenesis. Cell Rep. 14, 282–297 (2016).
Sangfelt, O. & Strander, H. Apoptosis and cell development inhibition as antitumor effector features of interferons. Med. Oncol. 18, 3–14 (2001).
Ivashkiv, L. B. IFNγ: signalling, epigenetics and roles in immunity, metabolism, illness and most cancers immunotherapy. Nat. Rev. Immunol. 18, 545–558 (2018).
Gao, Y. et al. γδ T cells present an early supply of interferon γ in tumor immunity. J. Exp. Med. 198, 433–442 (2003).
Adachi, Ok. & Chiba, Ok. FTY720 story. Its discovery and the next accelerated growth of sphingosine 1-phosphate receptor agonists as immunomodulators primarily based on reverse pharmacology. Perspect. Med. Chem. 1, 11–23 (2007).
Zheng, W. et al. Mixture of radiotherapy and vaccination overcome checkpoint blockade resistance. Oncotarget 7, 43039–43051 (2016).
Siddiqui, I. et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor management in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195–211.e10 (2019).
Cheng, N. et al. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive fashions of triple-negative breast most cancers. JCI perception https://doi.org/10.1172/jci.perception.120638 (2018).
Ohkuri, T., Kosaka, A., Nagato, T. & Kobayashi, H. Results of STING stimulation on macrophages: STING agonists polarize into ‘classically’ or ‘alternatively’ activated macrophages? Hum. Vaccin. Immunother. 14, 285–287 (2018).
You, L. et al. The crosstalk between autophagic and endo-/exosomal pathways in antigen processing for MHC presentation in anticancer T cell immune responses. J. Hematol. Oncol. 10, 165 (2017).
Delamarre, L., Pack, M., Chang, H., Mellman, I. & Trombetta, E. S. Differential lysosomal proteolysis in antigen-presenting cells determines antigen destiny. Science 307, 1630–1634 (2005).
Wu, J., Dobbs, N., Yang, Ok. & Yan, N. Interferon-independent actions of mammalian STING mediate antiviral response and tumor immune evasion. Immunity 53, 115–126.e5 (2020).
Smyth, M. J., Ngiow, S. F., Ribas, A. & Teng, M. W. L. Mixture most cancers immunotherapies tailor-made to the tumour microenvironment. Nat. Rev. Clin. Oncol. 13, 143–158 (2016).
Bush, N. A. O., Chang, S. M. & Berger, M. S. Present and future methods for remedy of glioma. Neurosurgic. Rev. 40, 1–14 (2017).
Filippone, A. et al. PD1/PD-L1 immune checkpoint as a possible goal for stopping mind tumor development. Most cancers Immunol. Immunother. 71, 2067–2075 (2022).
Ranoa, D. R. E. et al. Molecular cell biology STING promotes homeostasis by way of regulation of cell proliferation and chromosomal stability. Most cancers Res. 79, 1465–1479 (2019).
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet. J. 17, 10–12 (2011).
Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat. Biotechnol. 37, 907–915 (2019).
Liao, Y., Smyth, G. Ok. & Shi, W. FeatureCounts: an environment friendly normal function program for assigning sequence reads to genomic options. Bioinformatics https://doi.org/10.1093/bioinformatics/btt656 (2014).
Costa-Silva, J., Domingues, D. & Lopes, F. M. RNA-Seq differential expression evaluation: an prolonged overview and a software program software. PLoS ONE 12, e0190152 (2017).
Subramanian, A. et al. Gene set enrichment evaluation: a knowledge-based method for deciphering genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Orecchioni, M., Ghosheh, Y., Pramod, A. B. & Ley, Ok. Macrophage polarization: totally different gene signatures in M1(Lps+) vs. classically and M2(LPS–) vs. alternatively activated macrophages. Entrance. Immunol. https://doi.org/10.3389/fimmu.2019.01084 (2019).
[ad_2]